Abstract:Background: Lynch syndrome (LS) predisposes to endometrial cancer (EC), colorectal cancer, and other cancers through inherited pathogenic variants affecting mismatch-repair (MMR) genes. Diagnosing LS in women with EC can reduce subsequent cancer mortality through colonoscopic surveillance and aspirin chemoprevention; it also enables cascade testing of relatives. A growing consensus supports LS screening in EC; however, the expected proportion of test positives, and optimal testing strategy is uncertain. Previous studies from insurance-based healthcare systems were limited by narrow selection criteria, failure to apply reference standard tests consistently, and poor conversion to definitive testing. The aim of this study was to establish the prevalence of LS and the diagnostic accuracy of LS testing strategies in an unselected EC population. Methods and findings: This was a prospective cross-sectional study carried out at a large United Kingdom gynaecological cancer centre between October 2015 and January 2017. Women diagnosed with EC or atypical hyperplasia (AH) were offered LS testing. Tumours underwent MMR immunohistochemistry (IHC), microsatellite instability (MSI), and targeted MLH1-methylation testing. Women <50 years, with strong family histories and/or indicative tumour molecular features, underwent MMR germline sequencing. Somatic MMR sequencing was performed when indicative molecular features were unexplained by LS or MLH1-hypermethylation. The main outcome measures were the prevalence of LS in an unselected EC population and the diagnostic accuracy of clinical and tumour testing strategies for risk stratifying women with EC for MMR germline sequencing. In total, 500 women participated in the study; only 2 (<1%) declined. Germline sequencing was indicated and conducted for 136 and 135 women, respectively. A total of 16/500 women (3.2%, 95% CI 1.8% to 5.1%) had LS, and 11 more (2.2%) had MMR variants of uncertain significance. Restricting testing to age <50 years, indicative family history (revised Bethesda guidelines or Amsterdam II criteria) or endometrioid histology alone would have missed 9/16 (56%), 8/13 (62%) or 9/13 (69%), and 5/16 (31%) cases of LS, respectively. In total 132/500 tumours were MMR deficient by IHC of which 83/132 (63%) had MLH1-hypermethylation, and 16/49 (33%) of the remaining patients had LS (16/132 with MMR deficiency, 12%). MMR-IHC with targeted MLH1-methylation testing was more discriminatory for LS than MSI with targeted methylation testing, with 100% versus 56.3% (16/16 versus 9/16) sensitivity (p = 0.016) and equal 97.5% (468/484) specificity; 64% MSI-H and 73% MMR deficient tumours unexplained by LS or MLH1-hypermethylation had somatic MMR mutations. The main limitation of the study was failure to conduct MMR germline sequencing for the whole study population, which means that the sensitivity and specificity of tumour triage strategies for LS detection may be overestimated, although the risk of LS in women with no clinical or tumour predictors is expected to be extremely low. Conclusions: In this study, we observed that age, family history, and histology are imprecise clinical correlates of LS-EC. IHC outperformed MSI for tumour triage and reliably identified both germline and somatic MMR mutations. The 3.2% proportion of LS-EC is similar to colorectal cancer, supporting unselected screening of EC for LS.

Prevalence and predictors of aspirin/NSAID use among patients with Lynch syndrome (LS).

Perceptions of cancer prevention options for Lynch syndrome (LS) in a multi-national convenience sample.

Colorectal Neoplasia Detection Rates in Lynch Syndrome

Current chemoprevention approaches in Lynch syndrome and Familial adenomatous polyposis: a global clinical practice survey

Dietary behaviours of individuals with lynch syndrome at high risk of colorectal cancer: Results from the AAS-lynch study

Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome

Lynch Syndrome: From Multidisciplinary Management to Precision Prevention

Population-Level Identification of Patients With Lynch Syndrome for Clinical Care, Quality Improvement, and Research

The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study

Risk of Gastric and Small Intestinal Cancer in Patients With Lynch syndrome – Data From a Large, Community-Based U.S. Population

Colonoscopy and Upper Endoscopy Surveillance in Lynch Syndrome: A Longitudinal Study From a Large Tertiary Healthcare System

Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation

Abstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa

Diagnosis and management of Lynch syndrome

Lynch Syndrome: From Carcinogenesis to Prevention Interventions

Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

Perception about benefits and risks related to combined hormonal contraceptives use in women with Lynch syndrome

Quality of endoscopic surveillance of Lynch syndrome patients in a Swedish cohort

Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank

Inflammatory potential of the diet and colorectal tumor risk in persons with Lynch syndrome

Colonoscopy surveillance in Lynch syndrome is burdensome and frequently delayed